References
- Al-Lazikani B, Banerji U, Workman P (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol, 30, 679-92. https://doi.org/10.1038/nbt.2284
- Bock C, Lengauer T (2012). Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer, 12, 494-501. https://doi.org/10.1038/nrc3297
- Bouwman P, Jonkers J. (2012). The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer, 12, 587-98. https://doi.org/10.1038/nrc3342
- Burg D, Filippov DV, Hermanns R, et al (2002). Peptidomimetic glutathione analogues as novel gamma GT stable GST inhibitors. Bioorg Med Chem, 10, 195-205. https://doi.org/10.1016/S0968-0896(01)00269-3
- Gillet JP, Gottesman M. (2010). Mechanisms of multidrug resistance in cancer. Methods Mol Biol, 596, 47-76. https://doi.org/10.1007/978-1-60761-416-6_4
- Illuzzi JL, Wilson DM 3rd (2012). Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigms. Curr Med Chem, 19, 3922-36. https://doi.org/10.2174/092986712802002581
- Jemal A, Bray F, Center MM, Ferlay JE (2011). Ward and D. Forman: Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Larsen AK, Escargueil AE, Skladanowski A (2000). Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther, 85, 217-29. https://doi.org/10.1016/S0163-7258(99)00073-X
- L i M, Wang ZJ, Li WT, Dong ZM (2006). Establishment of a cisplatininduced human esophageal carcinoma drugresistant cell line and its biological characteristics. WCJD, 14, 3257-61. https://doi.org/10.11569/wcjd.v14.i34.3257
- L i M, Wang ZJ, Fu Q, Zhao GQ, Dong ZM (2007). Establishment of a cisplatin-induced human esophageal carcinoma drug resistant cell line and screening of drug resistance-related genes. Chin J Health Lab Technol, 17, 18-20.
- Li M, Zang WQ, Fu Q, Li WT, Dong ZM (2007). Correlation between overexpression ofDNA polymerase beta gene and drug-resistance of human esophageal carcinoma cells. J Fourth Mil Med Univ, 28, 1065-8.
- Liang XJ, Chen C, Zhao Y, Wang PC (2010). Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol, 596, 467-88. https://doi.org/10.1007/978-1-60761-416-6_21
- Li GC, Yang JM, Nie MM, et al (2005). Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma. Chin Med J, 118, 179-85.
- Liang XJ, Chen C, Zhao Y, Wang PC (2010). Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol, 596, 467-88. https://doi.org/10.1007/978-1-60761-416-6_21
- Li H, Zhou S, Li T (2012). Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrugresistant HCC cell line HEPG2/ADM by RNA interference. Hepatogastroenterology, 59, 2238-42.
- Maddalena F, Laudiero G, Piscazzi A, et al (2011). Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca (2+) homeostasis. Cancer Res, 71, 7659-69. https://doi.org/10.1158/0008-5472.CAN-11-2172
- Moroney J, Fu S, Moulder S,et al (2012). Phase I study of the antiangiogenic antibody bevacizumab and the mtor/hypoxiainducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res, 18, 5796-805. https://doi.org/10.1158/1078-0432.CCR-12-1158
- Rolland D, Raharijaona M, Barbarat A, Houlgatte R, Thieblemont C (2010). Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin. Anticancer Res, 30, 3951-7.
- Rygaard J, Povlsen CO (1969). Heterotransplantation of a humanmalignant tumour to "Nude" mice. Acta Pathol MicrobiolScand, 77, 758-60.
- Shen LZ, Hua YB, Yu XM, et al (2005). Tamoxifen can reversemultidrug resistance of colorectal carcinoma in vitro. WorldJ Gastroenterol, 11, 1060-4.
- Tang K, Lin Y, Li LM (2013). The role of phenethylisothiocyanate on bladder cancer ADM resistance reversaland its molecular mechanism. Anat Rec, 296, 899-906. https://doi.org/10.1002/ar.22677
- Wang AL, Few KD (1985). Increased glutathione-S-transferaseactivity in a cell line with acquired resistance to nitrogenmustards. Cancer Treat Rep, 69, 677-82.
-
Yin Q, Shen J, Chen L, et al (2012). Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly (
$\beta$ -amino esters). Biomaterials, 33, 6495-506. https://doi.org/10.1016/j.biomaterials.2012.05.039 - Yu DS, Hsieh DS, Chang SY (2006). Increasing expression ofGST-pi MIF, and ID1 genes in chemoresistant prostate cancercells. Arch Androl, 52, 275-81.
-
Zhao LJ, Xu H, Qu JW, et al (2012). Modulation of drug resistance in ovarian cancer cells by inhibition of protein kinase C-alpha
$(PKC-\alpha)$ with small interference RNA (siRNA) agents. Asian Pac J Cancer Prev, 13, 3631-42. https://doi.org/10.7314/APJCP.2012.13.8.3631